Boston Scientific Co. (BSX) Position Increased by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its stake in Boston Scientific Co. (NYSE:BSX) by 59.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 7,426,814 shares of the medical equipment provider’s stock after purchasing an additional 2,756,504 shares during the quarter. Two Sigma Advisers LP’s holdings in Boston Scientific were worth $184,111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Bollard Group LLC raised its position in Boston Scientific by 0.3% during the fourth quarter. Bollard Group LLC now owns 33,854,117 shares of the medical equipment provider’s stock worth $839,244,000 after acquiring an additional 118,050 shares during the last quarter. Geode Capital Management LLC raised its position in Boston Scientific by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 13,040,987 shares of the medical equipment provider’s stock worth $322,533,000 after acquiring an additional 373,607 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Boston Scientific by 29.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,945,671 shares of the medical equipment provider’s stock valued at $296,133,000 after buying an additional 2,705,194 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of Boston Scientific by 11.5% in the fourth quarter. OppenheimerFunds Inc. now owns 7,976,540 shares of the medical equipment provider’s stock valued at $197,739,000 after buying an additional 824,195 shares during the last quarter. Finally, Boston Partners raised its position in shares of Boston Scientific by 3.8% in the fourth quarter. Boston Partners now owns 7,475,797 shares of the medical equipment provider’s stock valued at $185,325,000 after buying an additional 276,390 shares during the last quarter. Hedge funds and other institutional investors own 91.85% of the company’s stock.

How to Become a New Pot Stock Millionaire

Boston Scientific Co. (BSX) traded up $0.10 during trading on Monday, reaching $28.64. 877,337 shares of the company were exchanged, compared to its average volume of 8,512,028. Boston Scientific Co. has a 52-week low of $24.02 and a 52-week high of $29.93. The stock has a market capitalization of $39,290.00, a P/E ratio of 40.83, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82. The company has a current ratio of 0.68, a quick ratio of 0.49 and a debt-to-equity ratio of 0.54.

Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. During the same period in the previous year, the firm earned $0.30 earnings per share. Boston Scientific’s revenue was up 9.9% compared to the same quarter last year. analysts anticipate that Boston Scientific Co. will post 1.37 EPS for the current fiscal year.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $25.25, for a total transaction of $399,833.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 85,227 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $26.48, for a total transaction of $2,256,810.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,276 shares of company stock valued at $4,592,464. 0.74% of the stock is owned by insiders.

BSX has been the subject of a number of analyst reports. Canaccord Genuity cut their price objective on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th. Oppenheimer reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. BTIG Research raised shares of Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Thursday, November 30th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $31.06.

TRADEMARK VIOLATION NOTICE: This article was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/03/12/boston-scientific-co-bsx-position-increased-by-two-sigma-advisers-lp.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply